Stryker (NYSE:SYK) Announces Quarterly Earnings Results

Stryker (NYSE:SYK) released its quarterly earnings data on Thursday. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.55 by ($0.03), FiscalAI reports. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. During the same quarter in the prior year, the company earned $3.19 EPS. Stryker’s quarterly revenue was up 7.6% on a year-over-year basis.

Here are the key takeaways from Stryker’s conference call:

• Hip and knee weakness pressured results: Stryker said the large-joint market has slowed to roughly 2.5% growth, citing affordability concerns, insurance-related preauthorization denials and softer international conditions. The company also acknowledged that cyber and SAP implementation disruptions hurt commercial execution and new-product adoption.
• Stryker lowered its 2026 outlook to 6.5%-7% organic sales growth and adjusted EPS of $14.80-$14.90, reflecting weaker hip and knee trends, lingering peripheral vascular supply constraints and a more conservative view of capital-equipment execution.
• Margins and cash generation remained strong: Third-quarter adjusted EPS rose 10.3% to $3.52, adjusted operating margin expanded 60 basis points to 26.2%, and year-to-date operating cash flow increased about 14% to $3.3 billion. The board also authorized an additional $3 billion for share repurchases.
• MedSurg and Neurotechnology grew 9.1%, led by Endoscopy, Medical and Vascular, while capital demand and the order book remained elevated. Stryker expects strong fourth-quarter contributions from Trauma and Extremities, Medical and Instruments, and highlighted upcoming growth drivers including AVS, new power-tool and endoscopy platforms, Mako products and the CMR Surgical robotics partnership.

Stryker Price Performance

Shares of NYSE SYK traded up $7.12 during midday trading on Thursday, reaching $311.12. The company’s stock had a trading volume of 3,059,300 shares, compared to its average volume of 2,477,724. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The business’s 50 day moving average price is $293.56 and its two-hundred day moving average price is $324.86. The company has a market cap of $119.33 billion, a P/E ratio of 21.79, a P/E/G ratio of 1.96 and a beta of 0.78.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Third-quarter revenue increased approximately 7.6% to $6.52 billion, while EPS rose to $3.52 from $3.19 a year earlier. Hospital equipment demand and ongoing recovery from the 2026 cybersecurity incident provided support. Stryker reports third quarter 2026 operating results
• Neutral Sentiment: Management’s earnings call highlighted continued demand for Stryker’s medical technology products, but investors are monitoring supply constraints and manufacturing issues affecting the vascular business, along with lingering operational effects from the cybersecurity incident. Stryker Q3 2026 earnings call transcript
• Negative Sentiment: Stryker lowered its 2026 outlook. Organic net sales growth is now expected at 6.5%–7.0%, versus the prior 8.3%–9.3% range, while adjusted EPS guidance fell to $14.80–$14.90 from $14.95–$15.10. The reduction signals that operational headwinds are expected to persist. Stryker lowers outlook after 3Q profit falls
• Negative Sentiment: Third-quarter EPS of $3.52 missed estimates of roughly $3.55–$3.56, and revenue of $6.52 billion was below the approximately $6.62 billion consensus. The sales shortfall and weaker outlook may weigh on valuation despite year-over-year growth. Stryker Q3 earnings and revenues lag estimates

Wall Street Analyst Weigh In

SYK has been the topic of several research analyst reports. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Royal Bank Of Canada reduced their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Citigroup decreased their target price on Stryker from $399.00 to $360.00 and set a “buy” rating on the stock in a research report on Thursday, September 10th. Finally, Canaccord Genuity Group lowered their target price on Stryker from $400.00 to $385.00 and set a “buy” rating on the stock in a research note on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $369.00.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last 90 days. 4.60% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.